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One of the most important functions of the skin besides regulating internal body
temperature includes formation of the barrier between the organism and the external
environment, hence protecting against pathogen invasion, chemical and physical
assaults and unregulated loss of water and solutes. Disruption of the protective barrier
is observed clinically in blisters and erosions of the skin that form in autoimmune
blistering diseases where the body produces autoantibodies against structural proteins
of the epidermis or the epidermal-dermal junction. Although there is no cure for
autoimmune skin blistering diseases, immune suppressive therapies currently available
offer opportunities for disease management. In cases where no treatment is sought,
these disorders can lead to life threatening complications and current research efforts
have focused on developing therapies that target autoantibodies which contribute
to disease symptoms. This review will outline the involvement of the skin barrier
in main skin-specific autoimmune blistering diseases by describing the mechanisms
underpinning skin autoimmunity and review current progress in development of
novel therapeutic approaches targeting the underlying causes of autoimmune skin
blistering diseases.
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INTRODUCTION
The stratified squamous epithelium of the human epidermis forms a continuous barrier against the
external environment and impairments in epithelial adhesions lead to disorders characterized by
significant morbidity and/or mortality (1). The hallmark feature of autoimmune blistering diseases
(AIBDs) is the disruption of the intact skin barrier as a consequence of blistering and erosions
caused by production of autoantibodies against structural proteins in the epidermis or at the
epidermal-dermal junction. AIBDs generally occur in the elderly, and often have substantial clinical
and immunopathological overlap and polymorphic clinical presentation which can make diagnosis
challenging (2). Immunologically, these conditions are driven by humoral and cellular autoimmune
responses directed against distinct target antigens and can be classed in threemain groups including
pemphigoid and pemphigus diseases as well as dermatitis herpetiformis (DH) (3).
Over the past four decades, our knowledge of the pathophysiology of AIBDs has been greatly
advanced by demonstrating that passive transfer of antibodies against skin antigens can disrupt
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the skin barrier and induce blisters in experimental animals
models with clinical, histologic, and immunopathogenic
responses similar to those observed in human disease (1).
Each AIBD is characterized by the presence of specific
autoantibodies targeting distinct antigens in the epidermis
or at the dermal-epidermal junction. Intraepidermal blistering
found in pemphigus disorders are caused by autoantibodies
targeting cadherin proteins in desmosomes; subtypes pemphigus
vulgaris and pemphigus foliaceus are associated with antibodies
against desmoglein (dsg)-3 and−1, respectively. In bullous
pemphigoid (BP), autoantibodies target two hemidesmosome
components BP180 and BP230; and in epidermolysis bullosa
acquisita (EBA) patients have autoantibodies target type VII
collagen anchoring fibrils. In DH patients, autoantibodies
target tissue and epidermal transglutaminase (eTG) proteins
(3) however recently a case was reported where autoimmune
intraepidermal and subepidermal blistering disease coexisted
with a patient who was reported to have autoantibodies to both
desmoglein (Dsg) 1 and BP230 (4).
AIBDs typically present with generalized blister eruption
associated with itch however atypical presentations are often
encountered. For example, 20% of BP patients present with “non-
bullous” presentations, while anti-p200 pemphigoid patients that
normally present with tense blisters with erythematosus often
show normal skin resembling BP. Additionally, epidermolysis
bullosa acquisita, an autoimmune disease associated with
autoantibodies against type VII collagen, has several phenotypes
including a classical form that mimics dystrophic epidermolysis
bullosa, an inflammatory form that mimics BP, or a form more
similar to mucous membrane pemphigoid-like lesions (2).
Diagnosis of AIBDs relies on direct immunofluorescence
microscopy studies and immunoserological assays (5, 6).
Multiple mechanisms of skin barrier disruption and blister
formation in AIBDs have been described: in pemphigus disorders
steric hindrance (the direct inhibition of protein-protein
binding by autoantibodies) and cell signaling events cause
desmosomal instability, while complement and inflammatory
cell activation mediated through Fc-signaling cause keratinocyte
death and blister formation in pemphigoid and epidermolysis
bullosa acquisita (7–9). Development of targeted therapies and
management of affected patients is often challenging due to
frequent relapses, lack of efficacy and number of adverse events
(10, 11). Current standard treatment options rely on non-specific
immunosuppression, highlighting the need for development
of targeted therapeutic approaches (12, 13). In this review
we will focus on skin barrier involvement in mechanisms
underpinning autoimmunity and describe the latest approaches
for development of targeted therapeutics for the treatment
of AIBDs.
SKIN BARRIER AND MECHANISMS
UNDERPINNING AUTOIMMUNE SKIN
BLISTERING
More than 2.5% of the world’s population is affected by
autoantibody driven autoimmune disease, including AIBDs
(7). The principles of autoantibody generation and detection
in AIBDs have been reviewed extensively (7). Technological
advancement in the last two decades have allowed us to identify
the sequence of specific nanostructural and functional changes
in the skin barrier following the binding of autoantibodies
and define critical pathways and processes responsible for
autoimmune pathology (14). The pathogenesis of AIBDs can
be divided into three phases: (i) the induction phase (loss of
self-tolerance or the initiation of autoimmunity to the target
antigen), (ii) the maintenance phase (maintained production
of autoantibodies) and (iii) the effector phase (autoantibody-
mediated tissue damage). Specific mechanisms relating to these
phases have been described for AIBDs, including pemphigus
disorders, BP, EBA, and DH.
INDUCTION OF AUTOIMMUNITY AGAINST
SKIN ANTIGENS
There are multiple theories that explain how the loss of tolerance
to self-antigens initially occurs and it is understood that the
majority of AIBDs are a product of several aberrant processes
which disrupt skin barrier homeostasis. Genetic factors play
an important role, as specific skin blistering diseases have
varying prevalence in different populations and inherited human
leukocyte antigen (HLA) types are associated with autoreactivity
to specific autoantigens (15). Multiple HLA alleles have been
identified which are associated with pemphigus vulgaris (15,
16), BP (17, 18), and EBA (19, 20). Genetic susceptibility is
not limited to HLA types, as pemphigus vulgaris has been
associated with mutations in ST18 (a gene encoding a pro-
apoptotic transcription factor) in certain populations (21) and
experimental models of EBA have identified non-HLA murine
gene loci that confer susceptibility to disease development (22),
however further studies are required to extrapolate these findings
to clinical populations.
Cell damage has been proposed as a common “triggering
factor” which causes development of pathogenic adaptive
autoimmune reactions—cell damage due to surgical trauma (23),
UV radiation (24), neurological disorders and other pre-existing
conditions (25–29), viral infection (30–33), and radiotherapy
(34–36) have all been associated with disrupted skin barrier
function and development of AIBDs (37). Cell damage via
necrosis or necroptosis releases a complex intracellular milieu
into the extracellular space which serves as a source of sensitizing
autoantigens (38); additionally cell death results in the release of
damage associated molecular patterns which stimulate localized
inflammation and wound healing processes (39, 40). Normal
healing responses following trauma aiming to re-establish the
skin barrier cause infiltration of dendritic cells and other antigen
presenting cells which may also participate in autoimmune
sensitization (41, 42) of AIBDs.
Epitope spreading is an inbuilt mechanism of the adaptive
immune system that aids in protecting against changing
pathogens (43), however spreading from pathogenic to
autologous epitopes and molecular mimicry of similar epitopes
may also contribute to the formation of AIBDs (44). Fogo
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selvage, an endemic form of pemphigus foliaceus found in
Brazilian populations, is associated with a history of sand fly
bites and characterized by autoantibodies against Dsg1. These
autoantibodies have shown cross reactivity to proteins present in
sand fly saliva (45), which may represent epitope spreading from
foreign proteins to similar autoantigens. Epitope spreading is
also thought to be involved in paraneoplastic (PNP) pemphigus
(46) where tumor-associated antigens may become targeted
in an effort to destroy the tumor, however similar antigens
may also be shared by keratinocytes (47). PNP pemphigus
is most commonly associated with lymphatic malignancies,
including non-Hodgkin’s lymphoma and chronic lymphocytic
leukemia. These malignancies are associated with the production
and release of cytokines which can lead to over-stimulation
of humoral immunity and autoimmune reactions, including
disruption of skin barrier and development of AIBDs. Findings
of autoimmune skin blistering in carcinoma patients has fuelled
speculation that these diseases may be triggered by an anti-tumor
immune response (48–50), however further studies are required
to determine the relationship between these findings (51, 52).
Coeliac-disease associated skin blistering, known as DH, is
caused by antibodies against gluten-induced digestive enzyme
tissue transglutaminase which undergo epitope spreading to
cross-react with epidermal transglutaminase (eTG) leading to
the disruption of the skin barrier and subsequent skin blistering
(53, 54). Epitope spreading may also contribute to the diversity
of and disease progression of AIBDs, as epitope spreading to
related autoantigens has been associated with atypical or altered
disease presentations (53, 55, 56).
AIBDs have been associated with the use of certain drugs
which trigger pathogenesis through a variety of mechanisms.
One of the most well-described etiologies is BP in diabetic
patients taking dipeptidyl-peptidase 4 (DPP-4) inhibitors (57–59)
which present with antibodies against the mid-portion of BP180.
It has been suggested that DPP-4 inhibition reduces plasmin
production and alters BP180 cleavage, resulting in altered
antigenicity of BP180 (60) which is supported by the finding that
symptoms generally subside after drug discontinuation. The use
of immune checkpoint inhibitors for cancer therapy has been
linked to secondary development of AIBD including mucous




Autoantibodies are often present in healthy individuals but
are generally non-pathogenic IgM antibodies with low affinity
present in low levels and do not alter skin barrier homeostasis.
For autoantibodies to gain pathogenicity, class-switching to IgG
or IgA subtypes, somatic mutation and increased production
occur after exposure to self-antigen. Glycosylation and sialylation
patterns on autoantibodies also contribute to pathogenicity and
antibodies stimulated via T-cell interaction within germinal
centers exhibit reduced sialyation patterns and are pro-
inflammatory (63). In the context of AIBDs, the presence of
self-antigen released by damaged keratinocytes may stimulate
production of autoantibodies, which in turn bind to healthy
tissue to stimulate skin barrier disruption and further tissue
damage and promote more autoantibody generation in a
self-perpetuating cycle. Continued production of pathogenic
autoantibodies may be achieved by ongoing B cell activation
and production of short-lived plasma cells (64, 65) or the
production of long-lived plasma cells which are challenging
to target (66–68). T-cell driven education within the germinal
center appears to be a requirement for the development of long-
lived plasma cells, which gives rise to both lasting immunity
against pathogens and chronic autoimmunity. Murine models
of EBA have also demonstrated the presence of plasma cells
with “intermediate” lifespans which contribute to autoantibody
persistence (69). Alterations in cellular immune networks also
contribute to maintained autoantibody production and disease
chronicity: Increased Th1 and Th17 cytokines and chemokines
have been reported in patients with pemphigus disorders (70, 71),
BP (72, 73), and DH (74) and changes in Treg populations
are also associated with AIBDs (75, 76), with Tregs thought
to be protective against pathogenic autoantibody production
(77, 78). Higher frequencies of Th17 cells secreting IL-21 have
been reported in pemphigus lesions which form a tertiary lymph
node like structure within the skin and promote autoantibody
production (79). Further investigation into cellular contributions
to autoantibody production may reveal additional therapeutic
targets which can be used to control AIBDs.
AUTOANTIBODY-INDUCED TISSUE
DAMAGE
Autoimmune diseases of the skin are the result of pathological
processes caused by autoantibodies against skin antigens. A
number of common antigens targeted by disease-associated
autoantibodies have been discovered, including antigens present
on desmosomes, hemidesmosomes and proteins expressed by
keratinocytes. Transfer of patient autoantibodies against Dsg 1
(80, 81) and Dsg 3 (82) and type VII collagen (83) is sufficient
to cause skin barrier disruption and epidermal blistering
in mice consistent with the associated clinical disease, thus
autoantibodies are considered instrumental to pathogenesis in
many AIBDs. Figure 1 provides a diagram summary of blistering
mechanisms and skin barrier disruption in prototypic AIBDs
pemphigus disorders, BP, EBA, and DH. Inflammation triggered
by autoantibody binding recruits and activates a number of
myeloid and lymphoid cell subsets that participate in blister
development and damage to the skin barrier, however these
vary with specific disease and clinical context. Previous reviews
have in details described the preclinical animal studies and some
clinical evidence elucidating the contributions of eosinophils
(84, 85), mast cells (86, 87), Th17 (70, 88), and Treg (89–91)
cells to AIBD’s, and thesemay represent novel therapeutic targets.
Here we focus on contributions of autoantibodies to skin barrier
disruption in different disease settings.
Unraveling the precise mechanisms of autoantibody-induced
pathology has been the focus of much research in recent
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FIGURE 1 | Blistering mechanisms of prototypic autoimmune skin blistering disorders result in skin barrier disruption. (A) Pemphigus disorders are caused by
autoantibodies against desmoglein (Dsg) proteins Dsg1 and Dsg3. Binding of anti-Dsg destabilizes desmosomes to cause acantholysis of keratinocytes within the
epidermis and triggers keratinocyte signal transduction events which promote inflammation, skin barrier disruption and further skin blistering. (B) Blisters in bullous
pemphigoid are caused by anti-BP180 antibodies which bind hemidesmosomes on basal keratinocytes and trigger complement activation and inflammatory
responses including ROS and protease release by neutrophils which directly kill keratinocytes. Skin barrier disruption and skin blistering is caused by keratinocyte
death and sustained localized inflammation. (C) Epidermolysis bullosa acquisita is caused by anti-Collagen VII antibodies which bind fibrils that anchor
hemidesmosomes to the basement membrane. Deposition of IgG induces complement activation via the classical pathway and activation of neutrophils. Basal
keratinocytes sustain damage via action of neutrophil-derived ROS and proteases resulting in splitting at the dermal-epidermal junction and skin barrier disruption. (D)
Dermatitis hepetiformis (DH) is caused by cross-reactive antibodies that bind epidermal transglutaminase (eTG). eTG is produced by keratinocytes and accumulates in
the papillary dermis where it forms immunogenic immune complexes with anti-eTG IgA that trigger complement activation. Fibrin deposition and influx of leukocytes
(which damage keratinocytes via release of ROS and proteases) cause the formation of neutrophilic abscesses which develop into fluid-filled subepidermal blisters
that disrupt the intact skin barrier.
years. Autoantibodies against Dsg proteins, as found in
pemphigus diseases, were initially thought to interfere with
Dsg-Dsg interactions in desmosomes by steric hindrance (92)
however evidence for direct effects of Dsg-anti-Dsg binding
on intracellular signaling events was later discovered, including
the p38 mitogen-activated protein kinase pathway leading to
acantholysis (93, 94). Anti-Dsg may also reduce the number of
desmosomes by clustering Dsg on the cell surface and interfering
with normal turnover of desmosomal proteins, thereby depleting
desmosomes of Dsg (95) and promoting acantholysis. In more
recent years, other autoantibody species (96–98) and non-
Dsg interactions (99) have been identified as contributing to
pemphigus pathology and have prompted the hypothesis that
multiple pathways may act synergistically (100) to cause classical
pemphigus disease pathology (101).
In BP, autoantibodies against BP180 and BP230 components
of hemidesmosomes produce blistering at the dermal-epidermal
junction. Activation of the complement cascade via classical and
alternative pathways has been demonstrated to contribute to skin
barrier disruption and BP pathology (102) and C3 deposition
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at the epidermal basement membrane is a common clinical
finding (103). Complement activation induces inflammation
and damages keratinocytes via cytotoxic action of neutrophils
leading to skin blistering and barrier disruption (104). Though
complement-independent mechanisms of BP pathology have
been since described (105, 106) including direct activation of
neutrophils via immune complex-FcγR binding, complement
activation is still a prevalent target for novel BP therapeutics
(103, 107). Autoreactive IgE and eosinophilia are common
findings in BP patients and IgE immune complexes binding and
activating eosinophils thereby contributing to blister formation
has been shown in in vitro and in vivo studies (108), implicating
eosinophils as potential therapeutic targets in BP.
Disease pathology in EBA is caused by predominantly
IgG1 and IgG3 autoantibodies that bind Collagen VII within
anchoring fibrils at the dermal-epidermal junction. As a rare
disease, much of what is known about EBA pathogenesis has
been elucidated with experimental models. Like BP, complement
activation is considered key to EBA pathogenesis (109),
however the alternative pathway appears to be the dominant
pathway behind experimental EBA pathology (110). Activation
of complement induces inflammation, leukocyte extraversion,
complement activation and subsequent tissue damage and
disruption of skin barrier via release of ROS and proteases
from neutrophils and other myeloid cells. Ex-vivo studies of
patient serum incubated with healthy skin and donor neutrophils
exhibit loss of epidermal adherence, hence clearly indicating
that antibodies mediate clinical EBA blistering via neutrophil
activation (111). The role of T cells in EBA pathology is yet to
be fully elucidated, however murine studies show that NKT and
γδT cells likely amplify tissue damage in EBA via interaction with
immune complexes and neutrophils (112).
DH is characterized by accumulation of ant-eTG IgA
antibodies within the papillary dermis, however eTG is
primarily expressed within superficial epidermal layers (113).
It is hypothesized that eTG may be released into the blood,
where interaction with IgA occurs in nearby dermal vessels;
alternatively eTG may be deposited along the basement
membrane as a result of trauma (54, 114), however further
research is required to confirm these hypotheses. Following IgA
deposition, papillary abscesses characterized by a neutrophilic
infiltrate and fibrin accumulation form which develop into a
split at the basement membrane and subepidermal blistering.
Patients with DH show reduced levels of anti-inflammatory IL-
10 and reduced Treg cell numbers in lesional skin compared to
healthy skin (115) which indicates the role of Tregs inmodulating




The use of different in-vitro systems and experimental
animal models in recent years has significantly improved
our understanding of AIBDs ultimately leading to novel
diagnostic tools and differentiated therapeutic approaches for
these disorders (6, 7, 75, 89, 109, 116–123). These approaches
can be broadly grouped into: traditional and topical therapies;
rituximab and intravenous immunoglobulins and other
treatments in pre-clinical and clinical trials. In this review, we
will provide a broad summary of traditional treatments and
novel emerging therapies which are also summarized in Table 1.
First line therapies for AIBDs generally include systemic
oral or intravenous corticosteroids (0.5–2.0 mg/kg/day) such
as prednisolone (12, 29). Topical high potency corticosteroids
such as clobetasol propionate have also been demonstrated
to be efficient alternatives to oral prednisolone therapy in
BP by reducing autoantibodies against BP180 and BP230 (2).
For more severe patients unresponsive to topical therapy, oral
prednisolone is combined with adjuvant immunosuppressant
(azathioprine, mycophenolate, or rituximab). Unlike other
AIBDs, oral corticosteroids do not normally have a dramatic
effect in EBA and to date there are no randomized controlled
trials providing level 1 evidence for EBA treatment (4). Milder
forms of EBA and DH may respond well to topical steroids
including dapsone or sulfapyridine, while rituximab has been
reported to be effective for severe patients (12, 61, 124, 140, 141).
Combining conventional systemic corticosteroids with rituximab
treatment has also showed beneficial clinical outcomes inmucous
membrane pemphigoid diseases (142).
Second line therapies include corticosteroid-sparing agents
azathioprine, mycophenolate mofetil, or rituximab, which
may be combined with intravenous immunoglobulin (IVIG)
therapy. Clinically, IVIG administration has been shown to
significantly improve BP disease symptoms for several weeks
after infusion (129). Third line therapies are dependent on
individual patient needs and include therapies in clinical trials:
cyclophosphamide, IgE-targeted therapies, immunoadsorption
to remove pathogenic autoantibodies, IVIG, methotrexate, and
plasma exchange.
Preclinical studies have identified potential emerging
therapies which target immunological mechanisms in AIBDs,
which aim to reduce damaging inflammatory processes. Direct
targeting of antibody-producing B cells is efficacious, as anti-
CD20 antibody (Rituximab) has been successfully used in the
clinic for multiple AIBDs, however not all patients respond
equally. Targeting other B cell markers including anti-CD19
and anti-CD22, or antigen-specific B cell receptors may
improve targeting of long-lived plasma cells which produce
pathogenic autoantibody in patients that are refractory to
rituximab. Therapies targeting components of the complement
cascade have exhibited success in preclinical and clinical trials,
however concerns with side effects associated with existing
complement targeting therapies may limit the clinical utility of
these approaches (143, 144). Previous studies have highlighted
the roles of cytokines in mediating AIBD tissue damage
and have identified multiple therapeutic targets including
TNFα (130, 145), IL-5 (84), IL-17A(117), and IL-1 blockade
(146) and administration of anti-inflammatory IL-10 (147).
Immunomodulatory anti-cytokine therapies are in various stages
of development, with existing TNF-α inhibitors showing efficacy
in treating AIBDs and antibodies against IL-5 and eotaxin-1
having entered clinical trials for BP treatment (148–150).
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TABLE 1 | Current and emerging therapeutic approaches in autoimmune skin blistering diseases.





Prednisolone (12, 124, 125)
Clobetasol propionate
Dapsone, Sulfapyridine




Second-line therapies BP, PD, EBA, DH
Antibody removal Immunoadsorption
Plasma exchange
Third-line therapies BP, PD, EBA, DH




















HSP-90 inhibition (135, 136)
SYK inhibition (137)





























Wound healing therapies Anti-Flii (139) Preclinical EBA
BCR, B-cell receptor; BP, Bullous pemphigoid; DH, dermatitis herpetiformis; EBA, epidermolysis bullosa acquisita; HSP, Heat-shock protein; IVIG, intravenous immunoglobulin; MMP,
mucous membrane pemphigoid; PD, pemphigus disorders; SYK, spleen tyrosine kinase.
Like immunomodulatory therapies for other autoimmune
diseases, these approaches are likely to be associated with
known side effects of immunosuppression (151) thus further
trials are needed to identify the safest and most efficacious
dose regimens for specific diseases. Preclinical studies have
identified cellular populations which may be exploited as
therapeutic targets, such as Langerhans cells (152), dendritic
cells (153), granulocytes (104, 111, 133, 154), and multiple
T cell subsets including Th17 (117, 155), Treg (75), NKT
(112), γδT (112), and CD8+ (156). Approaches to target
specific immune cell functions are currently in preclinical
development, including small molecule inhibition of spleen
tyrosine kinase (137), an enzyme involves in proinflammatory
Fc-receptor signal transduction in myeloid cells, and metabolites
of Vitamin D which reduce myeloid cell activation and ROS
production (122).
Understanding the mechanisms of autoantibody mediated
tissue damage is critical in development of novel targeted
therapies, however understanding the mechanisms behind
resolution of blistering and inflammation in AIBDs can
also offer insights into potential novel treatment modalities.
Unresolved blistering can impact patient quality of life and
increase risk of bleeding, infection and tumor development
(157). Optimal healing is especially important for patients
with extensive cutaneous blistering, or mucosal blistering
which affects feeding, digestion and function of other organs
(158, 159). Studies surrounding the role of Flightless protein
(Flii) in skin blistering have revealed the first mechanism
leading to the resolution of blistering and inflammation in
antibody transfer induced EBA (8), and further research into
similar pathways may reveal more potential therapeutic
strategies where wound healing therapies may offer
opportunities for decreasing the clinical symptoms associated
with AIBDs.
In summary, there is a high unmet need for new targeted
therapeutic approaches focussed on restoring the integrity of the
skins’ barrier 22and address both blistering mechanisms
and clinical symptoms in systemic AIBDs. Innovative
designs of randomized controlled trials using validated
scales of assessment are needed to drive the development
of novel therapeutic strategies for patients with AIBDs.
Additionally, research efforts should focus on adapting
immunomodulatory approaches that have been shown to
be effective in other autoimmune diseases in order to target
common pathogenic mechanisms and developing a better
understanding of blister resolution and healing to improve
patient symptoms.
CONCLUSION
As highlighted in this review, the contribution of the skin
barrier to the mechanisms underpinning autoimmunity has
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greatly improve our understanding of AIBDs. Development
of novel targeted therapeutics restoring skin barrier function
and homeostasis will lead to improved treatment of patients
with AIBDs.
CONTRIBUTION TO THE FIELD
STATEMENT
Autoimmune skin blistering diseases are caused by pathogenic
autoantibodies which trigger cellular, biochemical and
immunological processes that disrupt the skin barrier and cause
chronic blistering in patients. Understanding the mechanisms
behind these processes has lead to the development of new
targeted therapeutics which are in various stages of preclinical
and clinical development. Current therapeutic approaches rely
heavily on immunosuppressants and corticosteroids which
are associated with adverse effects including risk of infection.
Thus, new therapeutics are necessary to effectively control skin
blistering and restore the skin barrier with fewer side effects.
In this review, we highlight the different mechanisms behind
autoimmune skin blistering disease development including
initiation, maintenance and tissue damage. Additionally, we
summarize current treatment and emerging therapeutics for
autoimmune skin blistering diseases and highlight blistering
mechanisms which may be exploited for development of novel
targeted therapeutics.
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